Editas Medicine Inc
NASDAQ:EDIT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Beauty Garage Inc
TSE:3180
|
JP |
|
E
|
Estrella Immunopharma Inc
NASDAQ:ESLA
|
US |
|
Shanghai HeartCare Medical Technology Corp Ltd
HKEX:6609
|
CN |
|
S
|
Sinosoft Technology Group Ltd
HKEX:1297
|
CN |
Editas Medicine Inc
Other Liabilities
Editas Medicine Inc
Other Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Editas Medicine Inc
NASDAQ:EDIT
|
Other Liabilities
$59.4m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
9%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Liabilities
$32.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
24%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Liabilities
$2.1B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Liabilities
$5.1B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Liabilities
$3B
|
CAGR 3-Years
41%
|
CAGR 5-Years
36%
|
CAGR 10-Years
51%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Liabilities
$2.2B
|
CAGR 3-Years
47%
|
CAGR 5-Years
24%
|
CAGR 10-Years
11%
|
|
Editas Medicine Inc
Glance View
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 264 full-time employees. The company went IPO on 2016-02-03. The firm is focused on developing transformative gene editing medicines to treat a range of serious diseases. The company has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The firm is focused on both in vivo gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, and ex vivo gene-edited cell medicines, in which cells are edited with its technology. The firm's gene editing medicine programs include EDIT-101, EDIT-102, EDIT-103, EDIT-301 and EDIT-202.
See Also
What is Editas Medicine Inc's Other Liabilities?
Other Liabilities
59.4m
USD
Based on the financial report for Dec 31, 2025, Editas Medicine Inc's Other Liabilities amounts to 59.4m USD.
What is Editas Medicine Inc's Other Liabilities growth rate?
Other Liabilities CAGR 10Y
9%
Over the last year, the Other Liabilities growth was -24%. The average annual Other Liabilities growth rates for Editas Medicine Inc have been -14% over the past three years , -13% over the past five years , and 9% over the past ten years .
